Tenofovir (all routes except local)

Gestational diabetes

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5134
R13378		 Floridia, 2018 Diabetes/glucose metabolism abnormalities during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: No Control group: Abacavir/Lamivudine-based Exposed group: TDF/emtricitabine-based Indication: HIV 0.66 [0.36;1.20] 32/661   18/252 50 661
ref
S5127
R13309		 Ransom, 2013 Gestational diabetes during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 1.27 [0.82;1.97] C 33/630   58/1,395 91 630
ref
Total 2 studies 0.95 [0.50;1.80] 141 1,291
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Floridia, 2018Floridia, 2018 0.66[0.36; 1.20]5066145%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ransom, 2013Ransom, 2013 1.27[0.82; 1.97]9163055%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 67% 0.95[0.50; 1.80]1411,2910.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.95[0.50; 1.80]1411,29167%NAFloridia, 2018 Ransom, 2013 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 0.95[0.50; 1.80]1411,29167%NAFloridia, 2018 Ransom, 2013 2 Tags Adjustment   - No  - No 0.95[0.50; 1.80]1411,29167%NAFloridia, 2018 Ransom, 2013 2 Control group   - Abacavir/Lamivudine-based  - Abacavir/Lamivudine-based 0.66[0.36; 1.20]50661 -NAFloridia, 2018 1   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 1.27[0.82; 1.97]91630 -NARansom, 2013 1 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 1.27[0.82; 1.97]91630 -NARansom, 2013 1   - TDF/emtricitabine-based  - TDF/emtricitabine-based 0.66[0.36; 1.20]50661 -NAFloridia, 2018 1 Indication   - HIV  - HIV 0.95[0.50; 1.80]1411,29167%NAFloridia, 2018 Ransom, 2013 2 All studiesAll studies 0.95[0.50; 1.80]1411,29167%NAFloridia, 2018 Ransom, 2013 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.95[0.50; 1.80]1411,29167%NAFloridia, 2018 Ransom, 2013 20.510.01.0